Immunotherapy relies on the body’s own immune system to fight disease. The idea for immune therapy goes back to the late 19th century when Dr. William Coley injected bacteria into tumors and saw the tumors shrink. It was eventually discovered that the tumor cells were being killed by an immune response provoked by the injected bacteria. This suggests that the immune system has the power, when properly stimulated, to attack and even eliminate a growing cancer. However, due to the tremendous complexity of the immune system, scientists struggled for decades to turn Dr. Coley’s observations into effective cancer treatments.
 It’s only been recently that therapies based on modulating the immune system (other than vaccines) have made it into the clinic. Even with the initial limited success of immunotherapies there are now high expectations that immunotherapy will provide the next great breakthroughs in cancer treatment.

As stated by Max S. Wicha, director of the University of Michigan Cancer Center, “After years of research, we are now, for the first time, moving beyond the traditional cancer therapies of chemotherapy, radiation and surgery. One of the approaches we are most excited about is immunotherapy, because it is based on a fundamental knowledge of how the human immune system works and recognizes cancers to destroy them. It also fits in with other therapies of the future, which will use genetics and molecular biology to target cancers in a much more specific way."

 Immunotherapy offers great promise as a new tool for the treatment of cancer and many other diseases. Recent advances in our understanding of tumor immunology have greatly expanded the potential applicability of this therapeutic approach, with benefits now being seen in patients with tumor types not previously thought to be amenable to such treatment. These include patients with prostate, lung and brain cancers as well as a variety of hematologic malignancies, who have benefited from immunotherapy, either used alone or in combination with chemotherapy, radiation or surgery. Within the last few years, two cancer immunotherapy approaches have been approved by the FDA: Provenge® (Sipuleucel-T) for castration-resistant prostate cancer and YERVOY™ (anti-CTLA-4 monoclonal antibody) for patients with advanced stages of melanoma.

 Further, exciting advances are on the horizon with opportunities to develop combinations of either active immunotherapies or an immunotherapy together or with novel molecularly targeted therapies, which raise the potential for prolongation of survival in a large percentage of patients whose diseases were previously felt to be incurable.
$30.00 USD

Cardio Support

(228 reviews)
$30.00 USD
Designed with builders of all ages in mind, this collection of LEGO® bricks in 35 different colors will encourage open-ended building play, and inspire any imagination.

Video Testimonials

The following videos contain testimonials regarding the use of the commercially available pine cone extract, Immune Extra, a dietary supplement developed at the Tampa Bay Research Institute. The testimonies describe the use of the supplement to strengthen the immune system in conditions ranging from allergies to cancer. The opinions expressed here are solely those of the people volunteering their testimonies. These videos were kindly recorded and produced by John Sipos.

Bill Allard talks about his miraculous recovery from cancer.

Liza talks about a cancer scare and her "little miracle".

Ed and Gloria talk about the miraculous response of their son's cancer (cutaneous T cell lymphoma) to therapy and the pine cone extract.

Jane talks about her friends battle with metastatic breast cancer and her positive response when using the pine cone extract.